COVID-19治疗综述:治疗性药物再利用与未满足的临床需求
本文综述了COVID-19大流行初期基于有限临床证据的药物再利用尝试,指出多数早期临床试验存在设计缺陷、样本量小、非随机或治疗时机不同等问题,而针对无症状、轻症或儿科病例的良好设计研究极为缺乏。基于现有证据可观察到:瑞德西韦和法匹拉韦可能缩短恢复时间;洛匹那韦/利托那韦对重症患者未显示疗效;利巴韦林、洛匹那韦和干扰素β-1b三联疗法显示早期病毒转阴,主要效应可能与干扰素有关;白细胞介素-6抑制剂、恢复期血浆在小型研究中显示可能获益;羟氯喹或氯喹的作用尚不明确;中药联合抗病毒药物可能减轻重症患者炎症。抗病毒药物与免疫调节药物联合治疗对伴有细胞因子释放综合征的危重症患者合理,而抑制细胞因子释放的药物对早期轻症或晚期危重症患者可能无益。
要点
- 瑞德西韦和法匹拉韦可能缩短恢复时间,洛匹那韦/利托那韦对重症患者无效。
- 中药联合抗病毒药物可能减轻重症COVID-19患者炎症,值得进一步研究。
- 亟需针对儿童、轻症或早期COVID-19患者开展专门临床试验。
核心结论
- 基于当前临床证据可观察到部分药物趋势,但多数研究存在设计缺陷,儿童及轻症患者研究亟需开展。
研究设计与样本
- 本文为综述,基于当前临床证据总结COVID-19治疗选择。
- 多数已发表研究纳入重症或危重症COVID-19患者。
主要发现
- 瑞德西韦和法匹拉韦可能缩短恢复时间。
- 洛匹那韦/利托那韦在重症患者中未显示治疗疗效。
- 利巴韦林、洛匹那韦和干扰素β-1b三联疗法显示早期病毒转阴,主要效应可能与干扰素有关。
- 小型研究显示白细胞介素-6抑制剂可能显示临床改善,恢复期血浆可能使非危重患者受益。
- 羟氯喹或氯喹在COVID-19治疗和预防中的作用尚不明确。
关键数值与推荐
- 中药联合抗病毒药物(如干扰素、洛匹那韦或阿比多尔)可能减轻重症COVID-19患者炎症,基于小型观察性研究和专家意见。
- 抗病毒药物与免疫调节药物联合治疗对伴有细胞因子释放综合征的危重症COVID-19患者合理。
- 抑制细胞因子释放的药物对早期轻症或晚期危重症患者可能无益。
临床怎么用
- 根据现有证据趋势选择抗病毒药物,但需注意研究局限性。
- 对重症特别是伴有细胞因子释放综合征患者可考虑抗病毒联合免疫调节治疗。
- 中药联合抗病毒药物可用于减轻重症患者炎症,但需进一步研究。
局限性
- 多数早期临床试验存在设计缺陷、样本量小、非随机设计或治疗开始时间不同等问题。
- 无症状、轻症或儿科COVID-19病例的良好设计研究稀缺。
- 部分证据基于小型观察性研究或专家意见。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
For the initial phase of pandemic of coronavirus disease 2019 (COVID-19), repurposing drugs that in vitro inhibit severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) have been attempted with overlooked or overestimated efficacy owing to limited clinical evidence. Most early clinical trials have the defects of study design, small sample size, non-randomized design, or different timings of treatment initiation. However, well-designed studies on asymptomatic or mild, or pediatric cases of COVID-19 are scarce and desperately needed to meet the clinical need. However, a trend could be observed based on current clinical evidence. Remdesivir and favipiravir may shorten the recovery time; lopinavir/ritonavir does not demonstrate treatment efficacy in severe patients. Triple therapy of ribavirin, lopinavir, and interferon β-1b showed early viral negative conversion, and the major effect may be related to interferon. Some small sample-size studies showed that interleukin-6 inhibitors may demonstrate clinical improvement; non-critical patients may benefit from convalescent plasma infusion in small sample-size studies; and the role of hydroxychloroquine or chloroquine in the treatment and prophylaxis of COVID-19 remains unclear. Combination therapy of traditional Chinese medicine with antiviral agents (ex. interferon, lopinavir, or arbidol) may alleviate inflammation in severe COVID-19 patients based on small sample-sized observational studies and experts' opinion. Most of the published studies included severe or critical patients with COVID-19. Combination therapy of antiviral agents and immune-modulating drugs is reasonable especially for those critical COVID-19 patients with cytokine release syndrome. Drugs to blunt cytokine release might not benefit for patients in the early stage with mild disease or the late stage with critical illness. Traditional Chinese medicine with antiviral effects on SARS-CoV-2 and immune-modulation is widely used for COVID-19 patients in China, and is worthy of further studies. In this review, we aim to highlight the available therapeutic options for COVID-19 based on current clinical evidence and encourage clinical trials specific for children and for patients with mild disease or at the early stage of COVID-19.
引用
- Chen PL, Lee NY, Cia CT, et al. A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs. Front Pharmacol. 2020. PMID: 33364959. doi:10.3389/fphar.2020.584956
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。